Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Contribution of Different Relapse Phenotypes to Disability in Multiple Sclerosis Publisher Pubmed



Stewart T1 ; Spelman T1, 2 ; Havrdova E3 ; Horakova D3 ; Trojano M4 ; Izquierdo G5 ; Duquette P6 ; Girard M6 ; Prat A6 ; Lugaresi A7 ; Grandmaison F8 ; Grammond P9 ; Sola P10 ; Shaygannejad V11 Show All Authors
Authors
  1. Stewart T1
  2. Spelman T1, 2
  3. Havrdova E3
  4. Horakova D3
  5. Trojano M4
  6. Izquierdo G5
  7. Duquette P6
  8. Girard M6
  9. Prat A6
  10. Lugaresi A7
  11. Grandmaison F8
  12. Grammond P9
  13. Sola P10
  14. Shaygannejad V11
  15. Hupperts R12
  16. Alroughani R13
  17. Orejaguevara C14
  18. Pucci E15
  19. Boz C16
  20. Lechnerscott J17
  21. Bergamaschi R18
  22. Van Pesch V19
  23. Iuliano G20
  24. Ramo C21
  25. Taylor B22
  26. Slee M23
  27. Spitaleri D24
  28. Granella F25
  29. Verheul F26
  30. Mccombe P27
  31. Hodgkinson S28
  32. Amato MP29
  33. Vucic S30
  34. Gray O31
  35. Cristiano E32
  36. Barnett M33
  37. Sanchez Menoyo JL34
  38. Van Munster E35
  39. Saladino ML36
  40. Olascoaga J37
  41. Prevost J38
  42. Deri N39
  43. Shaw C40
  44. Singhal B41
  45. Moore F42
  46. Rozsa C43
  47. Shuey N44
  48. Skibina O45
  49. Kister I46
  50. Petkovskaboskova T47
  51. Ampapa R48
  52. Kermode A49, 50
  53. Butzkueven H1, 51, 52
  54. Jokubaitis V1, 2
  55. Kalincik T1, 2

Source: Multiple Sclerosis Published:2017


Abstract

Objective: This study evaluated the effect of relapse phenotype on disability accumulation in multiple sclerosis. Methods: Analysis of prospectively collected data was conducted in 19,504 patients with relapse-onset multiple sclerosis and minimum 1-year prospective follow-up from the MSBase cohort study. Multivariable linear regression models assessed associations between relapse incidence, phenotype and changes in disability (quantified with Expanded Disability Status Scale and its Functional System scores). Sensitivity analyses were conducted. Results: In 34,858 relapses recorded during 136,462 patient-years (median follow-up 5.9 years), higher relapse incidence was associated with greater disability accumulation (β = 0.16, p < 0.001). Relapses of all phenotypes promoted disability accumulation, with the most pronounced increase associated with pyramidal (β = 0.27 (0.25-0.29)), cerebellar (β = 0.35 (0.30-0.39)) and bowel/bladder (β = 0.42 (0.35-0.49)) phenotypes (mean (95% confidence interval)). Higher incidence of each relapse phenotype was associated with an increase in disability in the corresponding neurological domain, as well as anatomically related domains. Conclusion: Relapses are associated with accumulation of neurological disability. Relapses in pyramidal, cerebellar and bowel/bladder systems have the greatest association with disability change. Therefore, prevention of these relapses is an important objective of disease-modifying therapy. The differential impact of relapse phenotypes on disability outcomes could influence management of treatment failure in multiple sclerosis. © SAGE Publications.
Other Related Docs
6. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
13. Disability Accrual in Primary and Secondary Progressive Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2023)
14. Early Predictors of Conversion to Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)